Vaxcyte, Inc.

$55.63

$1.65(3.05%)

Vaxcyte, Inc.

PCVX

$55.63

$1.65(3.05%)

Vaxcyte, Inc.

PCVX

NASDAQ

$55.63

$1.65(3.05%)

Chart

Upcoming Earnings

Next report date

May 6, 2026

Report period

Q2 2026

EPS Estimate

$-1.86

Revenue Estimate

—

Key stats

52-Week Range$55.63

$27.66

$76.61

Market capitalization

$8.00B

Dividend yield (indicated)

0.00%

Price to earnings Ratio (TTM)

-10.34

Basic EPS (TTM)

$-5.63

Net income (TTM)

$-766.63M

Revenue (TTM)

$0.00

Avg. volume

1.36M

Beta (1Y)

1.38

Employees

414

Market capitalization

$8.00B

Dividend yield (indicated)

0.00%

Price to earnings Ratio (TTM)

-10.34

Basic EPS (TTM)

$-5.63

Net income (TTM)

$-766.63M

Revenue (TTM)

$0.00

Avg. volume

1.36M

Beta (1Y)

1.38

Employees

414

Screener Quick Check

About Vaxcyte, Inc.

Sector

Healthcare

Industry

Biotechnology

CEO

Grant E. Pickering

Website

vaxcyte.com

Headquarters

825 Industrial Road, San Carlos, CA, 94070

IPO Date

2020-06-12

Identifiers

ISINUS92243G1085

Description

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial...

Related Stocks

Arrowhead Pharmaceuticals, Inc.

ARWR

$57.37Mkt Cap: $8.03B

Healthcare

Biotechnology

ISIN:US04280A1007

Metsera, Inc.

MTSR

$70.50Mkt Cap: $7.43B

Healthcare

Biotechnology

ISIN:US59267L1070

Dividend Overview

This company does not pay dividends

Financials

Performance

Margin trends

Debt level and coverage

Earnings

Next: Q2 '26

Actual

Estimate

Earnings

Next: Q2 '26

Actual

Estimate

Performance

Margin trends

Debt level and coverage

Earnings

Next: Q2 '26

Actual

Estimate

Earnings

Next: Q2 '26

Actual

Estimate